Patents by Inventor Steve Ruben

Steve Ruben has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20120076725
    Abstract: Methods and compositions are provided for assessing (e.g., diagnosing), treating, and preventing diseases, especially cancer, and particular lung cancer, using lung cancer markers (LCM). Individual LCM and panels comprising multiple LCM are provided for these and other uses. Methods and compositions are also provided for determining or predicting the effectiveness of a treatment or for selecting a treatment using LCM. Methods and compositions are further provided for modulating cell function using LCM. Also provided are compositions that modulate LCM (e.g., antagonists or agonists), such as antibodies, proteins, small molecule compounds, and nucleic acid agents (e.g., RNAi and antisense agents), as well as pharmaceutical compositions thereof. Further provided are methods of screening for agents that modulate LCM, and agents identified by these screening methods.
    Type: Application
    Filed: January 12, 2011
    Publication date: March 29, 2012
    Applicant: CELERA CORPORATION
    Inventors: Charles BIRSE, Marcia LEWIS, Steve RUBEN, Mehdi MESRI
  • Patent number: 8110373
    Abstract: Methods and compositions for diagnosing and treating diseases, particularly cancer, associated with differential expression of cancer-associated targets (CAT) in disease cells compared to healthy cells are provided. Also provided are antagonists and agonists of CAT, and methods for screening agents that modulate CAT level or activity in vivo or in vitro.
    Type: Grant
    Filed: July 17, 2009
    Date of Patent: February 7, 2012
    Assignee: Celera Corporation
    Inventors: Steve Ruben, Candy N. Lee, Bruno Domon
  • Publication number: 20110271357
    Abstract: The present invention provides a method for diagnosing and detecting diseases associated with colon. The present invention provides one or more proteins or fragments thereof, peptides or nucleic acid molecules differentially expressed in colon diseases (CCAT) and antibodies binds to CCAT. The present invention provides that CCAT is used as targets for screening agents that modulates the CCAT activities. Further the present invention provides methods for treating diseases associated with colon.
    Type: Application
    Filed: October 25, 2010
    Publication date: November 3, 2011
    Applicant: CELERA CORPORATION
    Inventors: Yeounjin KIM, Tao HE, Steve RUBEN
  • Publication number: 20110250204
    Abstract: Methods and compositions are provided for assessing, treating, and preventing diseases, especially cancer, using cancer-associated targets (CAT). Methods and compositions are also provided for determining or predicting the effectiveness of a treatment for these diseases or for selecting a treatment, using CAT. Methods and compositions are further provided for modulating cell function using CAT. Also provided are compositions that modulate CAT (e.g., antagonists or agonists), such as antibodies, proteins, small molecule compounds, and nucleic acid agents (e.g., RNAi and antisense agents), as well as pharmaceutical compositions thereof. Further provided are methods of screening for agents that modulate CAT, and agents identified by these screening methods.
    Type: Application
    Filed: October 8, 2010
    Publication date: October 13, 2011
    Applicant: CELERA CORPORATION
    Inventors: Steve RUBEN, Paul A. MOORE, Tao HE, Candy N. LEE, Karen VAN ORDEN, Charles E. Birse, Mehdi Mesri, Elizabeth G. Joseloff
  • Publication number: 20110212085
    Abstract: The present invention provides a method for diagnosing and detecting diseases associated with lung. The present invention provides one or more proteins or fragments thereof, peptides or nucleic acid molecules differentially expressed in lung diseases (LCAT) and antibodies binds to LCATs. The present invention provides that LCATs are used as targets for screening agents that modulates the LCAT activities. Further the present invention provides methods for treating diseases associated with lung.
    Type: Application
    Filed: August 19, 2010
    Publication date: September 1, 2011
    Applicant: CELERA CORPORATION
    Inventors: Elizabeth JOSELOFF, Aiqun LI, Tao HE, Steve RUBEN
  • Patent number: 7998689
    Abstract: The present invention provides a method for diagnosing and detecting diseases associated with kidney. The present invention provides one or more proteins or fragments thereof, peptides or nucleic acid molecules differentially expressed in kidney diseases (KCAT) and antibodies binds to KCATs. The present invention provides that KCATs are used as targets for screening agents that modulates the KCAT activities. Further the present invention provides methods for treating diseases associated with kidney.
    Type: Grant
    Filed: September 10, 2009
    Date of Patent: August 16, 2011
    Assignee: Celera Corporation
    Inventors: Elizabeth Joseloff, Steve Ruben, Tao He, Yeounjin Kim
  • Publication number: 20110093962
    Abstract: The present invention provides a method for diagnosing and detecting diseases associated with breast. The present invention provides one or more proteins or fragments thereof, peptides or nucleic acid molecules differentially expressed in breast diseases (BCAT) and antibodies binds to BCAT. The present invention provides that BCAT is used as targets for screening agents that modulates the BCAT activities. Further the present invention provides methods for treating diseases associated with breast.
    Type: Application
    Filed: October 22, 2010
    Publication date: April 21, 2011
    Applicant: CELERA CORPORATION
    Inventors: Jenny HEIDBRINK, Steve RUBEN, Charles E. BIRSE, Tao HE
  • Patent number: 7892760
    Abstract: Methods and compositions are provided for assessing (e.g., diagnosing), treating, and preventing diseases, especially cancer, and particular lung cancer, using lung cancer markers (LCM). Individual LCM and panels comprising multiple LCM are provided for these and other uses. Methods and compositions are also provided for determining or predicting the effectiveness of a treatment or for selecting a treatment using LCM. Methods and compositions are further provided for modulating cell function using LCM. Also provided are compositions that modulate LCM (e.g., antagonists or agonists), such as antibodies, proteins, small molecule compounds, and nucleic acid agents (e.g., RNAi and antisense agents), as well as pharmaceutical compositions thereof. Further provided are methods of screening for agents that modulate LCM, and agents identified by these screening methods.
    Type: Grant
    Filed: November 19, 2008
    Date of Patent: February 22, 2011
    Assignee: Celera Corporation
    Inventors: Charles Birse, Marcia Lewis, Steve Ruben, Mehdi Mesri
  • Patent number: 7842467
    Abstract: The present invention provides a method for diagnosing and detecting diseases associated with breast. The present invention provides one or more proteins or fragments thereof, peptides or nucleic acid molecules differentially expressed in breast diseases (BCAT) and antibodies binds to BCAT. The present invention provides that BCAT is used as targets for screening agents that modulates the BCAT activities. Further the present invention provides methods for treating diseases associated with breast.
    Type: Grant
    Filed: May 29, 2008
    Date of Patent: November 30, 2010
    Assignee: Celera Corporation
    Inventors: Jenny Heidbrink, Steve Ruben, Charles E. Birse, Tao He
  • Patent number: 7842291
    Abstract: Methods and compositions are provided for assessing, treating, and preventing diseases, especially cancer, using cancer-associated targets (CAT). Methods and compositions are also provided for determining or predicting the effectiveness of a treatment for these diseases or for selecting a treatment, using CAT. Methods and compositions are further provided for modulating cell function using CAT. Also provided are compositions that modulate CAT (e.g., antagonists or agonists), such as antibodies, proteins, small molecule compounds, and nucleic acid agents (e.g., RNAi and antisense agents), as well as pharmaceutical compositions thereof. Further provided are methods of screening for agents that modulate CAT, and agents identified by these screening methods.
    Type: Grant
    Filed: May 22, 2007
    Date of Patent: November 30, 2010
    Assignee: Celera Corporation
    Inventors: Steve Ruben, Paul A. Moore, Tao He, Candy N. Lee, Karen Van Orden, Charles E. Birse, Mehdi Mesri, Elizabeth G. Joseloff
  • Patent number: 7842466
    Abstract: The present invention provides a method for diagnosing and detecting diseases associated with colon. The present invention provides one or more proteins or fragments thereof, peptides or nucleic acid molecules differentially expressed in colon diseases (CCAT) and antibodies binds to CCAT. The present invention provides that CCAT is used as targets for screening agents that modulates the CCAT activities. Further the present invention provides methods for treating diseases associated with colon.
    Type: Grant
    Filed: February 19, 2008
    Date of Patent: November 30, 2010
    Assignee: Celera Corporation
    Inventors: Yeounjin Kim, Tao He, Steve Ruben
  • Publication number: 20100239581
    Abstract: The present invention provides a method for diagnosing and detecting diseases associated with kidney. The present invention provides one or more proteins or fragments thereof, peptides or nucleic acid molecules differentially expressed in kidney diseases (KCAT) and antibodies binds to KCATs. The present invention provides that KCATs are used as targets for screening agents that modulates the KCAT activities. Further the present invention provides methods for treating diseases associated with kidney.
    Type: Application
    Filed: September 10, 2009
    Publication date: September 23, 2010
    Applicant: CELERA CORPORATION
    Inventors: Elizabeth JOSELOFF, Steve RUBEN, Tao HE, Yeounjin KIM
  • Patent number: 7776555
    Abstract: The present invention provides a method for diagnosing and detecting diseases associated with colon. The present invention provides one or more proteins or fragments thereof, peptides or nucleic acid molecules differentially expressed in colon diseases (CCAT) and antibodies binds to CCAT. The present invention provides that CCAT is used as targets for screening agents that modulates the CCAT activities. Further the present invention provides methods for treating diseases associated with colon.
    Type: Grant
    Filed: July 2, 2007
    Date of Patent: August 17, 2010
    Assignee: Celera Corporation
    Inventors: Bruno Domon, Steve Ruben, Charles E. Birse, Yeoun Jin Kim, Tao He, Ian McCaffery
  • Publication number: 20100061977
    Abstract: Methods and compositions for diagnosing and treating diseases, particularly cancer, associated with differential expression of cancer-associated targets (CAT) in disease cells compared to healthy cells are provided. Also provided are antagonists and agonists of CAT, and methods for screening agents that modulate CAT level or activity in vivo or in vitro.
    Type: Application
    Filed: July 17, 2009
    Publication date: March 11, 2010
    Applicant: CELERA CORPORATION
    Inventors: Steve RUBEN, Karen VAN ORDEN, Candy N. LEE, Tao HE, Mehdi MESRI, Elizabeth G. JOSELOFF, Paul MOORE, Katherine MCKINNON, Bruno DOMON
  • Publication number: 20100040637
    Abstract: Methods and compositions for detecting and treating diseases, especially cancer, and particularly breast, bladder, colon, gastrointestinal, kidney, liver, lung, melanoma, ovary, pancreatic, pharyngeal, prostate cancer and renal, associated with differential expression of prominin-1 (CD133) in disease cells compared to healthy cells. Also provided are antagonists or agonists of prominin-1, and methods for screening agents that modulate the prominin-1 level or activity in vivo or in vitro.
    Type: Application
    Filed: November 22, 2006
    Publication date: February 18, 2010
    Inventors: Karen Van Orden, Maria Leai Smith, Albina Nesterova, Candy Lee, Steve Ruben
  • Patent number: 7611703
    Abstract: The present invention provides a method for diagnosing and detecting diseases associated with kidney. The present invention provides one or more proteins or fragments thereof, peptides or nucleic acid molecules differentially expressed in kidney diseases (KCAT) and antibodies binds to KCATs. The present invention provides that KCATs are used as targets for screening agents that modulates the KCAT activities. Further the present invention provides methods for treating diseases associated with kidney.
    Type: Grant
    Filed: March 13, 2007
    Date of Patent: November 3, 2009
    Assignee: Celera Corporation
    Inventors: Elizabeth G. Joseloff, Yeoun Jin Kim, Tao He, Steve Ruben
  • Patent number: 7608413
    Abstract: The present invention provides a method for diagnosing and detecting diseases associated with kidney. The present invention provides one or more proteins or fragments thereof, peptides or nucleic acid molecules differentially expressed in kidney diseases (KCAT) and antibodies binds to KCATs. The present invention provides that KCATs are used as targets for screening agents that modulates the KCAT activities. Further the present invention provides methods for treating diseases associated with kidney.
    Type: Grant
    Filed: July 20, 2007
    Date of Patent: October 27, 2009
    Assignee: Celera Corporation
    Inventors: Elizabeth Joseloff, Steve Ruben, Tao He, Yeoun Jim Kim
  • Patent number: 7582441
    Abstract: Methods and compositions for diagnosing and treating diseases, particularly cancer, associated with differential expression of cancer-associated targets (CAT) in disease cells compared to healthy cells are provided. Also provided are antagonists and agonists of CAT, and methods for screening agents that modulate CAT level or activity in vivo or in vitro.
    Type: Grant
    Filed: December 7, 2006
    Date of Patent: September 1, 2009
    Assignee: Celera Corporation
    Inventors: Steve Ruben, Candy N. Lee, Bruno Domon
  • Publication number: 20090196873
    Abstract: Methods and compositions for detecting and treating a disease, particularly cancer, associated with differential expression of CDCP1 in disease cells compared to healthy cells. Also provided are antagonists or agonists of CDCP1, and methods for screening agents that modulate the CDCP1 level or activity in vivo or in vitro.
    Type: Application
    Filed: June 6, 2008
    Publication date: August 6, 2009
    Applicant: APPLERA CORPORATION
    Inventors: Bruno Domon, Charles E. Birse, Candy Lee, Steve Ruben
  • Publication number: 20090123461
    Abstract: The present invention provides a method for diagnosing and detecting cancer. The present invention provides one or more proteins or fragments thereof, peptides or nucleic acid molecules differentially expressed in cancer (podocalyxin) and antibodies that bind podocalyxins. The present invention provides that podocalyxins are used as targets for screening agents that modulate podocalyxin activities. Further the present invention provides methods for treating diseases associated with podocalyxin expression.
    Type: Application
    Filed: October 21, 2008
    Publication date: May 14, 2009
    Applicant: Celera Corporation
    Inventors: William Fitzhugh, Steve Ruben, Vaibhav Narayan, Charles E. Birse